1. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population
- Author
-
Francesco Persico, Arturo Brunetti, Giovanni Rusconi, Andrea Ponsiglione, Ferdinando Fusco, Sirio Cocozza, Mario Petretta, Renato Cuocolo, Arnaldo Stanzione, Massimo Imbriaco, Nicola Longo, Cuocolo, Renato, Stanzione, Arnaldo, Rusconi, Giovanni, Petretta, Mario, Ponsiglione, Andrea, Fusco, Ferdinando, Longo, Nicola, Persico, Francesco, Cocozza, Sirio, Brunetti, Arturo, Imbriaco, Massimo, Cuocolo, R., Stanzione, A., Rusconi, G., Petretta, M., Ponsiglione, A., Fusco, F., Longo, N., Persico, F., Cocozza, S., Brunetti, A., and Imbriaco, M.
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Psa density ,030232 urology & nephrology ,Predictive Value of Test ,Logistic regression ,Prostate specific antigen density ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Retrospective Studie ,Prostate ,Predictive Value of Tests ,Biopsy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Bi-parametric MR ,Aged ,Retrospective Studies ,Aged, 80 and over ,Receiver operating characteristic ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,General Medicine ,Organ Size ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Predictive value ,Magnetic Resonance Imaging ,Biopsy-naïve patient ,Patient population ,medicine.anatomical_structure ,ROC Curve ,Prostatic Neoplasm ,Radiology ,business ,Human - Abstract
Purpose: Bi-parametric prostate MR (bp-MR) is a valuable tool for detection and characterization of prostate cancer (PCa). Recent studies suggested that PSA-density (PSA-D) in combination with multi-parametric prostate MR as well as bp-MR may achieve a higher diagnostic accuracy than either alone. We aimed to evaluate the diagnostic performance of bp-MR, PSA-D and their combination in biopsy-naïve patients. Methods and materials: We retrospectively analyzed 334 consecutive patients who underwent prostate MR on a 3T scanner. Only patients (n = 114) who underwent TRUS-biopsy within 30 days following MR with no previous prostate biopsies were considered. Our protocol included T2-weighted and DWI sequences. A Likert score based on PI-RADS v2 was used for bp-MR evaluation. Lesions were graded histopathologically using the ISUP score. We assessed three scenarios: detection of lesions independently of ISUP score (ISUP ≥ 1), detection of both intermediate and clinically significant lesions (ISUP ≥ 2) and detection of clinically significant lesions alone (ISUP ≥ 3). Predictive value of bp-MR and PSA-D was evaluated by ROC curves and logistic regression analysis. A p value < 0.05 was considered statistically significant. Results: In all evaluated scenarios, bp-MR showed a significantly higher predictive power (AUC = 0.87-0.95) compared to the performance of PSA-D (AUC = 0.73–0.79), while their combination (AUC = 0.91-0.95) showed no statistically significant improvement compared to bp-MR alone. Conclusion: Our results confirm that bp-MR is a powerful tool in detection of clinically significant PCa. Contrary to findings in the recent literature, PSA-D does not appear to significantly improve its diagnostic performance.
- Published
- 2017